Dyne Therapeutics Inc’s recently made public that its CEO & President Cox John unloaded Company’s shares for reported $35402.0 on Sep 05 ’25. In the deal valued at $13.41 per share,2,640 shares were sold. As a result of this transaction, Cox John now holds 199,539 shares worth roughly $2.8 million.
Then, Friedl-Naderer Johanna sold 894 shares, generating $11,863 in total proceeds. Upon selling the shares at $13.27, the Chief Commercial Officer now owns 95,017 shares.
Before that, Friedl-Naderer Johanna sold 144 shares. Dyne Therapeutics Inc shares valued at $1,931 were divested by the Chief Commercial Officer at a price of $13.41 per share. As a result of the transaction, Friedl-Naderer Johanna now holds 94,873 shares, worth roughly $1.33 million.
Oppenheimer downgraded its Dyne Therapeutics Inc [DYN] rating to a Perform from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including Raymond James’s analysts, who increased its forecast for the stock in late August from “an Outperform” to “a Strong buy”. Bernstein began covering DYN with “Mkt perform” recommendation on June 24, 2025.
Price Performance Review of DYN
On Monday, Dyne Therapeutics Inc [NASDAQ:DYN] saw its stock fall -0.14% to $14.03. Over the last five days, the stock has gained 10.91%. Dyne Therapeutics Inc shares have fallen nearly -56.18% since the year began. Nevertheless, the stocks have fallen -40.45% over the past one year.
How much short interest is there in Dyne Therapeutics Inc?
A steep rise in short interest was recorded in Dyne Therapeutics Inc stocks on 2025-09-30, growing by 1.73 million shares to a total of 17.77 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 16.04 million shares. There was a rise of 9.73%, which implies that there is a positive sentiment for the stock.
